Chesapeake Urology Announces Dr. Sankar Kausik’s Designation as UroLift® Center of Excellence

Share Article

Designation Recognizes Dr. Sankar Kausik’s Commitment to Exemplary Care, Deep UroLift Experience

News Image
The UroLift System is a breakthrough minimally invasive treatment that typically takes less than an hour and can offer multiple benefits for men with enlarged prostate.

Chesapeake Urology today announced that Dr. Sankar Kausik has been designated as a UroLift® Center of Excellence. The designation recognizes that Dr. Kausik has achieved a high level of training and experience with the UroLift System and demonstrated a commitment to exemplary care for men suffering from symptoms associated with Benign Prostatic Hyperplasia or BPH.

“The UroLift System is a breakthrough minimally invasive treatment that typically takes less than an hour and can offer multiple benefits for men with enlarged prostate – no cutting, heating, or removal of tissue, minimal downtime, no compromise of sexual function, and no need for continued medications,” said Dr. Kausik. “I am proud to be a national leader offering this breakthrough treatment option.”

Nearly 40 million men in the United States are affected by BPH. Not to be confused with prostate cancer, BPH occurs when the prostate gland that surrounds the male urethra becomes enlarged with advancing age and begins to obstruct the urinary system. Symptoms of BPH often include interrupted sleep and urinary problems, and can cause loss of productivity, depression and decreased quality of life.

Five-year data from a randomized study shows the UroLift System offers not only rapid improvement, but also durable relief for patients with BPH. After five years, patients treated with the UroLift System continue to experience symptom relief with minimal side effects, with few patients requiring an additional procedure for relief. A second randomized clinical trial called BPH6 demonstrated that the minimally invasive UroLift System compares very well to the reference standard surgery, transurethral resection of the prostate (TURP), with regard to efficacy, and is superior to TURP at preserving sexual function and offering a more rapid recovery.

Medication is often the first-line therapy for enlarged prostate, but relief can be inadequate and temporary. Side effects of medication treatment can include sexual dysfunction, dizziness and headaches, prompting many patients to quit using the drugs. For these patients, the classic alternative is surgery that cuts, heats or removes prostate tissue to open the blocked urethra. While current surgical options can be very effective in relieving symptoms, they can also leave patients with permanent side effects such as urinary incontinence, erectile dysfunction and retrograde ejaculation.

About the UroLift System
NeoTract’s FDA-cleared UroLift System is a novel, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function. Patients also experienced a significant improvement in quality of life. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The UroLift System is available in the U.S., Europe, Australia, Canada, Mexico and South Korea. Learn more at http://www.UroLift.com.

About Chesapeake Urology
Chesapeake Urology is a fully-integrated urology practice providing a comprehensive array of urologic services to its patients. The Company, including its Urological Consultants division, operates 25 medical offices and 17 AAAHC-certified ambulatory surgery centers in Baltimore, Harford, Howard, Carroll, Montgomery, Prince George’s, and Anne Arundel counties and in Baltimore City, and has a staff of more than 725 including 87 physicians, 80 which are urologists. Chesapeake has been named one of the top places to work in healthcare nationally by Modern Healthcare magazine and Becker’s ASC Review, and locally by the Baltimore Sun, Baltimore magazine and the Baltimore Business Journal. For information about Chesapeake Urology, please visit http://www.ChesapeakeUrology.com.

#  #  #

Media Contact:
Patricia Schnably
Chesapeake Urology Associates
O: 443-738-8107
pschnably(at)cua(dot)md

1. Roehrborn et al. EAU Abstract_ Eur Urol Suppl 2017; 16(3):e192.
2. Sonksen et al J Urology 2016

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Nicole Hill
NeoTract Inc.
+1 (925) 201-8285
Email >

Patricia Schnably